- Home
- SIGA vs GLUE Comparison
SIGA vs GLUE Comparison
Compare SIGA & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIGA
- GLUE
- Stock Information
- Founded
- SIGA 1995
- GLUE 2019
- Country
- SIGA United States
- GLUE United States
- Employees
- SIGA N/A
- GLUE N/A
- Industry
- SIGA Biotechnology: Pharmaceutical Preparations
- GLUE Biotechnology: Pharmaceutical Preparations
- Sector
- SIGA Health Care
- GLUE Health Care
- Exchange
- SIGA Nasdaq
- GLUE Nasdaq
- Market Cap
- SIGA 551.0M
- GLUE 475.5M
- IPO Year
- SIGA 1997
- GLUE 2021
- Fundamental
- Price
- SIGA $5.94
- GLUE $6.93
- Analyst Decision
- SIGA
- GLUE Buy
- Analyst Count
- SIGA 0
- GLUE 3
- Target Price
- SIGA N/A
- GLUE $12.67
- AVG Volume (30 Days)
- SIGA 567.4K
- GLUE 1.8M
- Earning Date
- SIGA 11-07-2024
- GLUE 11-07-2024
- Dividend Yield
- SIGA 10.15%
- GLUE N/A
- EPS Growth
- SIGA N/A
- GLUE N/A
- EPS
- SIGA 1.20
- GLUE N/A
- Revenue
- SIGA $173,731,386.00
- GLUE $14,975,000.00
- Revenue This Year
- SIGA $16.79
- GLUE N/A
- Revenue Next Year
- SIGA $15.08
- GLUE N/A
- P/E Ratio
- SIGA $4.94
- GLUE N/A
- Revenue Growth
- SIGA 399.31
- GLUE N/A
- 52 Week Low
- SIGA $4.26
- GLUE $3.21
- 52 Week High
- SIGA $12.83
- GLUE $12.40
- Technical
- Relative Strength Index (RSI)
- SIGA 38.74
- GLUE 39.61
- Support Level
- SIGA $5.62
- GLUE $6.15
- Resistance Level
- SIGA $6.23
- GLUE $7.95
- Average True Range (ATR)
- SIGA 0.43
- GLUE 0.88
- MACD
- SIGA -0.07
- GLUE -0.34
- Stochastic Oscillator
- SIGA 19.02
- GLUE 17.18
About SIGA SIGA Technologies Inc.
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
About GLUE Monte Rosa Therapeutics Inc.
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their most advanced product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.